Greenstone

Greenstone Biosciences is a computational biology and drug discovery company focused on developing therapies for cardiovascular and rare diseases using induced pluripotent stem cell (iPSC) technology. The company leverages its proprietary G-REDI platform, which combines patient-derived iPSCs with artificial intelligence and high-throughput screening to model diseases "in a dish" and identify novel therapeutic candidates. By utilizing a massive biobank of patient-specific cells, Greenstone aims to accelerate the transition from bench to bedside while improving the predictive accuracy of preclinical models. Their current pipeline primarily targets genetic cardiomyopathies and neuromuscular disorders with a focus on precision medicine.